Schrodinger, Inc.

Listed Company

SDGRCIK 0001490978NasdaqLarge AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$255.87M

Net Income

$-103.27M

Total Assets

$726.16M

Equity

$364.05M

Shares Out

62.98M

Op. Cash Flow

$13.90M

Business

Schrödinger, Inc. provides a physics-based computational platform that enables discovery and optimization of molecules for drug development and materials science. It offers software solutions and enterprise informatics for target identification, hit discovery, lead optimization, large-scale molecule enumeration/evaluation and visualization, as well as collaborative and proprietary drug discovery services and research collaborations. The company operates key business lines in software licensing, collaborative drug discovery programs and a proprietary therapeutics pipeline. Its customers include biopharmaceutical and industrial companies, academic institutions and government labs served globally via direct sales and distribution channels.

Summary from filing dated 2025-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	256	208	217	181	138
Total cost of revenues	113	75	76	80	72
Gross profit	143	132	141	101	66
Research and development	173	202	182	126	91
Sales and marketing	41	40	37	31	22
General and administrative	95	100	99	91	64
Total operating expenses	310	341	318	248	177
Loss from operations	−167	−209	−177	−147	−111
Gain on equity investments	0	0	147	12	−2
Change in fair value of equity investments	48	6	53	−18	11
Other income	16	18	20	4	1
Total other income	65	24	220	−2	11
(Loss) income before income taxes	−102	−186	43	−149	−101
Income tax expense	939,000	1	2	63,000	411,000
Net (loss) income	−103	−187	41	−149	−100
Net (loss) income per share attributable to common and limited common stockholders, basic (in USD per share)	−1.41	−2.57	0.57	−2.1	−1.42
Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, basic (in shares)	73	73	72	71	71
Net (loss) income per share of common and limited common stockholders, diluted (in USD per share)	−1.41	−2.57	0.54	−2.1	−1.42
Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, diluted (in shares)	73	73	75	71	71

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	231	147	155	90	120
Restricted cash	7	15	6	5	3
Marketable securities	165	205	308	361	456
Accounts receivable, net of allowance for doubtful accounts of $440 and $210	83	236	66	56	32
Unbilled and other receivables, net of allowance for unbilled receivables of $140 and $100	21	20	23	13	9
Prepaid expenses	13	12	10	9	5
Total current assets	519	635	568	534	625
Property and equipment, net	19	24	23	14	—
Equity investments	74	43	83	26	43
Goodwill	5	5	5	5	0
Right of use assets - operating leases	103	112	118	106	75
Other assets	6	4	6	3	3
Total assets	726	823	803	689	756
Accounts payable	11	11	17	9	8
Accrued payroll, taxes, and benefits	39	42	32	25	18
Deferred revenue	113	112	56	58	55
Lease liabilities - operating leases	16	17	17	11	2
Other accrued liabilities	9	10	12	6	7
Total current liabilities	189	192	134	109	91
Deferred revenue, long-term	79	109	9	26	30
Lease liabilities - operating leases, long-term	93	101	111	105	78
Other liabilities, long-term	1	146,000	667,000	800,000	300,000
Total liabilities	362	402	254	241	199
Commitments and contingencies (Note 6)	—	—	—	—	—
Preferred stock, $0.01 par value. Authorized 10,000,000 shares; zero shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	0	0	0	0	0
Additional paid-in capital	992	946	886	829	787
Accumulated deficit	−629	−526	−338	−379	−230
Accumulated other comprehensive income	107,000	220,000	281,000	−2	−651,000
Total stockholders' equity	364	421	549	448	557
Total liabilities and stockholders' equity	726	823	803	689	756

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Changes in fair value of equity investments	−48	−6	−53	18	−11
Depreciation and amortization	6	6	6	4	3
Stock-based compensation	43	50	48	40	26
Noncash investment accretion	−2	−8	−8	629,000	5
Loss on disposal of property and equipment	20,000	8,000	142,000	19,000	140,000
Accounts receivable, net	153	−170	−10	−24	−321,000
Unbilled and other receivables	−2	3	−10	−4	−5
Reduction in the carrying amount of right of use assets - operating leases	9	9	8	7	6
Prepaid expenses and other assets	−2	−3	−8	−7	−1
Accounts payable	908,000	−6	7	1	−411,000
Accrued payroll, taxes, and benefits	−3	10	7	6	6
Deferred revenue	−29	155	−18	−2	−1
Lease liabilities - operating leases	−9	−10	−4	2	−3
Other accrued liabilities	91,000	−2	6	−1	3
Net cash provided by (used in) operating activities	14	−157	−137	−120	−71
Purchases of property and equipment	−1	−7	−13	−8	−7
Purchases of equity investments	0	−3	−4	−600,000	−4
Distribution from equity investment	0	0	147	12	375,000
Proceeds from sale and disposition of equity investments	18	49	0	0	16
Purchases of marketable securities	−313	−251	−321	−271	−415
Proceeds from maturity of marketable securities	355	362	384	365	393
Net cash provided by investing activities	58	149	193	90	−17
Proceeds from issuances of common stock upon stock option exercises	3	1	9	2	—
Proceeds from issuance of common stock in ATM offering	0	9	0	0	—
Payment of offering costs	0	−177,000	−373,000	0	0
Principal payments on finance leases	−58,000	−58,000	−19,000	0	0
Net cash provided by financing activities	3	10	9	2	8
Net increase in cash and cash equivalents and restricted cash	75	2	65	−28	−80
Purchases of property and equipment in accounts payable	40,000	162,000	192,000	169,000	705,000
Purchases of property and equipment in accrued liabilities	81,000	157,000	457,000	293,000	0
Acquisition of right of use assets - operating leases, contingency resolution	0	3	514,000	2	0
Acquisition of right of use assets in exchange for lease liabilities - operating leases	0	0	15	35	71
Acquisition of right of use assets in exchange for lease liabilities - finance leases	0	0	279,000	0	71

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro